BMD

BMD (BioMedical Diagnostics), founded by ex-members of Abbott Diagnostic, is pioneering the development of in vitro diagnostic (IVD) kits based on several unique technologies, including multiplex analysis (e.g. the xMAP® technology whose licence was acquired from Luminex® in 1999). Today, BMD is a leader in the development, manufacturing and marketing of innovative IVDs. The company currently sells 10 proprietary kits in its FIDIS™ range for the diagnosis of auto-immune diseases and 30 proprietary ELISAs and DOT assays.

BMD recently achieved the CE mark for its LISA TRACKER Premium kits, designed for monitoring patients undergoing treatment for autoimmune diseases. They enable the simultaneous assay of TNFalpha, anti-TNF therapeutics including infliximab, Etanercept, and adalimumab, and neutralizing antidrug antibodies. Truffle Capital is the majority shareholder of BMD.

Truffle Capital board member: Dr. Philippe Pouletty, Antoine Pau